BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25837857)

  • 1. Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.
    Chan JY; Choudhury Y; Tan MH
    Expert Rev Mol Diagn; 2015 May; 15(5):631-46. PubMed ID: 25837857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal cell carcinoma and proteomics.
    Sandim V; Pereira DA; Ornellas AA; Alves G
    Urol Int; 2010; 84(4):373-7. PubMed ID: 20224258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genomics of renal cell carcinoma and its role in renal mass biopsy.
    Salami SS; George AK; Udager AM
    Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.
    Hsieh JJ; Le V; Cao D; Cheng EH; Creighton CJ
    J Pathol; 2018 Apr; 244(5):525-537. PubMed ID: 29266437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
    Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
    J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in renal cell carcinoma.
    Shuch BM; Lam JS; Belldegrun AS; Figlin RA
    Semin Oncol; 2006 Oct; 33(5):563-75. PubMed ID: 17045085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of renal cell carcinoma.
    Ngo TC; Wood CG; Karam JA
    Urol Oncol; 2014 Apr; 32(3):243-51. PubMed ID: 24239464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma.
    Czarnecka AM; Kornakiewicz A; Kukwa W; Szczylik C
    Future Oncol; 2014 May; 10(6):1095-111. PubMed ID: 24941992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages: results from a proteomic study integrated with bioinformatics analysis.
    Zhang L; Jiang H; Xu G; Wen H; Gu B; Liu J; Mao S; Na R; Jing Y; Ding Q; Zhang Y
    Mol Med Rep; 2015 Jun; 11(6):4093-100. PubMed ID: 25673070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biomarkers in advanced renal cell carcinoma.
    Maroto P; Rini B
    Clin Cancer Res; 2014 Apr; 20(8):2060-71. PubMed ID: 24526734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteomic landscape of renal tumors.
    Chinello C; L'imperio V; Stella M; Smith AJ; Bovo G; Grasso A; Grasso M; Raimondo F; Pitto M; Pagni F; Magni F
    Expert Rev Proteomics; 2016 Dec; 13(12):1103-1120. PubMed ID: 27748142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.
    Pagni F; Guerini-Rocco E; Schultheis AM; Grazia G; Rijavec E; Ghidini M; Lopez G; Venetis K; Croci GA; Malapelle U; Fusco N
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genitourinary imaging: part 2, role of imaging in medical management of advanced renal cell carcinoma.
    Shinagare AB; Krajewski KM; Jagannathan JP; Ramaiya NH
    AJR Am J Roentgenol; 2012 Nov; 199(5):W554-64. PubMed ID: 23096199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer proteomics: developments in technology, clinical use and commercialization.
    Yeat NC; Lin C; Sager M; Lin J
    Expert Rev Proteomics; 2015 Aug; 12(4):391-405. PubMed ID: 26145529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.
    Fotia G; Stellato M; Guadalupi V; Sepe P; Claps M; Giannatempo P; Bottiglieri A; Rametta A; Taglialatela I; Vela C; Procopio G; Verzoni E
    Curr Oncol Rep; 2023 Jun; 25(6):671-677. PubMed ID: 37000341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.
    Bex A; Gore M; Mulders P; Sternberg CN
    BJU Int; 2012 Nov; 110(9):1289-300. PubMed ID: 22624610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.